Terug
naar lijst
- Auteur
- NVMO-commissie BOM
- Printdatum
- 20-02-2025
- E-pubdatum
- 11-02-2025
- Bron
- Medische Oncologie
Plaatsbepaling PARP-remmers als onderhoudsbehandeling na primaire behandeling FIGO stadium III-IV hooggradig ovariumcarcinoom
In Nederland zijn momenteel olaparib (SOLO-1-studie) en niraparib (PRIMA-studie) beschikbaar als onderhoudsbehandeling bij een primair stadium III-IV hooggradig epitheliaal ovariumcarcinoom … Verder lezen “Plaatsbepaling PARP-remmers als onderhoudsbehandeling na primaire behandeling FIGO stadium III-IV hooggradig ovariumcarcinoom”
- Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375(22):2154-64.
- Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 2016;17(11):1579-89.
- Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495-505.
- Banerjee S, Moore KN, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22 (12):1721-31.
- DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2022;41(3):609-17.
- Ray-Coquard I, Pautier P, Pignata S et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med 2019;381(25);2416-28.
- Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92
- González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019;381(25):2391-402.
- Li N, Zhu J, Yin R, et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer a phase 3 randomized clinical trial. JAMA Oncol 2023;9(9):1230-3.
- Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase iii trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol 2022;40(34):3952-64.
- Monk BJ, Barretina-Ginesta MP, Pothuri B, et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol 2024;35(11):981-92.